The C0 IGLL5+ Myeloma Cells subgroup, characterized by the expression of IGLL5, was selected for further investigation due to its robust differentiation ability, high degree of malignancy, and alignment with lineage1. This evidence concerns the gene IGLL5 and plasma cell myeloma.